Contact information


Academic education

2003 - 2010 Medical School, University of Göttingen, Germany/Royal Infirmary Edinburgh, UK


Scientific degrees

04/2019 DKTK W3 Professorship (full professor), Dept. of Medicine II
07/2012 MD, Institute for Cellular and Molecular Immunology, Georg August University Göttingen. Entitled: The organisation of signaling networks in B cells. Advisor: Prof. Wienands (Grade: Summa cum laude)
06/2010 Graduation from Medical School, Georg August University Göttingen


Scientific career

2023 - present Director, Department of Hematology and Oncology, University Hospital Frankfurt
2019 - 2023 Director, Lymphoma Clinic
2019 - present Head of the Molecular Diagnostics Program, Frankfurt Cancer Institute
2017 - 2019 Project leader/Research collaboratorNational Cancer Institute, NIH, Lymphoid Malignancies Branch, USA (director: Louis Staudt))
2015 - 2017 Project leader/Research collaborator, University of Cambridge, Department of Haematology, UK (director: Tony Green)
2014 - 2018 Steering committee member, LOEWE Center for Cell and Gene Therapy Frankfurt (CGT, funding: 40.419.080,00 €)
2018 - present Director DKTK Proteomics Core Facility Frankfurt
2014 - present Research group leader University Hospital Frankfurt, Department of Hematology/Oncology


Honors/ Awards/ Memberships

2018 Johann Georg Zimmermann Research Award
2018 Artur-Pappenheim Research Award
2016 GILEAD Research Award Oncology
2012 Publication Award of the Georg August University Göttingen
2002 Award of the German Society of Physics


  • LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1

    Microenvironmental bystander cells are essential for the progression of chronic lymphocytic leukemia (CLL). We have discovered previously that LYN kinase promotes the formation of a microenvironmental niche for CLL. Here we provide mechanistic evidence that LYN regulates the polarization of stromal…

  • Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

    Hypomethylating agents decitabine and azacytidine are regarded as interchangeable in the treatment of acute myeloid leukemia (AML). However, their mechanisms of action remain incompletely understood, and predictive biomarkers for HMA efficacy are lacking. Here, we show that the bioactive metabolite…

  • Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia

    Spleen tyrosine kinase (SYK) is a nonmutated therapeutic target in acute myeloid leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown promising results in combination with chemotherapy, likely reflecting induced mechanisms of resistance to single-agent treatment in vivo. We…